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In studies measuring dichotomous outcomes, relative risk (RR) is a standard measure for comparing
study groups. The purpose of using RR is to adjust for baseline variability in the occurrence of 
disease. It is easier to compare two trials on the basis of their RR estimates than on the basis of their
absolute effects.
The relative effect should also be calculated for continuous outcomes. Although the duration
of disease may vary randomly in placebo groups, there are also biological reasons why diseases in 
different placebo groups differ in their severity and duration. For example, in Analysis 1.1 of this 
review, the duration of influenza-like illness in the placebo group of trial WV15671 is 35% shorter 
than in the placebo group of trial WV15819/WV15876/WV15978 (Z = 6.5; P = <0.00001; 
125h/192h). Such very large baseline differences are not explained by chance. Differences in the 
study populations, influenza seasons, study protocols, etc. are plausible explanations for the 
baseline variation. The above-mentioned baseline difference is much greater than any of those 
between the oseltamivir (Tamiflu) and placebo groups in the five trials of Analysis 1.1. As for 
dichotomous outcomes, the baseline variability of continuous outcomes can be adjusted for by 
calculating the effect in percentages, i.e., the relative effect. Furthermore, the percentage effect is 
informative for an average reader because the reader may form an opinion on whether, for example,
a 10% or 20% average decrease in the duration is worth the cost and effort of the treatment. 
Separate from the absolute effect in days, the percentage effect shows whether the effect is small or 
large.
Therefore the effect of oseltamivir should be calculated also as a percentage effect. 
I calculated the relative effects for the five trials listed in Analysis 1.1, pooled them using the fixed 
effect inverse variance method of RevMan, and found that the average effect of oseltamivir is 
a 13% (95% CI: 8 to 18%) decrease in the duration of influenza-like illness.
Furthermore, the relative effect estimate makes it possible to compare the effects of 
treatments for related conditions. Influenza-like illness has substantial overlap with the common 
cold. In our Cochrane review on vitamin C and the common cold we calculated that ≥1 g/day of 
vitamin C shortens colds in adults by 8% (95% CI: 4 to 12%) and in children by 18% (95% CI: 
9 to 27%) [1]. Another meta-analysis found that a high dose of zinc (>75 mg/day) as zinc acetate 
lozenges decreased the duration of colds by 42% (95% CI: 35 to 48%) and as zinc lozenges made 
with other salts by 20% (95% CI: 12 to 28%)[2]. The mechanism of the effect of vitamin C and zinc
lozenges is not understood; however, there is no reason to assume that their effects are specific, for 
example, to the rhinovirus. If vitamin C and zinc lozenges have effects on diverse respiratory 
viruses, they might also have an effect on influenza viruses. In mice, influenza infection decreased 
vitamin C concentration in bronchoalveolar lavage fluid [3]. In mice, vitamin C deficiency 
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increased lung pathology caused by influenza infection [4]. An early study with influenza patients 
reported that the occurrence of pneumonia was 80% lower (2 vs. 10 cases) in the vitamin C group, 
suggesting that vitamin C might also have an effect on influenza in humans [5,6]. If the effects of 
vitamin C and zinc lozenges on influenza-like illness are of the same magnitude as their effects on 
the common cold, then the effects of these treatments compare reasonably with oseltamivir. The 
comparison of the percentage effects of oseltamivir, vitamin C and zinc lozenges may be useful 
when considering how future research resources concerning the treatment of respiratory virus 
infections might be allocated. In this respect, the type of effect measure has a much wider 
importance than just its use in evaluating the effectiveness of oseltamivir as an issue of its own.
Thus the relative effect estimate adjusts for baseline variations between trials, it is 
informative for most readers because people are familiar with percentages, and it makes it easier to 
compare different treatments for related conditions. For these reasons I would like to encourage the 
authors to calculate and report the relative effect estimates for oseltamivir in the next revision of the
review.
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